Eswatini vs Iraq: Average cost of drugs for extensively drug-resistant tuberculosis
Eswatini
2,726 constant 2022 US$
in 2024
Iraq
2,000 constant 2022 US$
in 2024
Eswatini rank
22nd
Iraq rank
24th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Eswatini
- Iraq
How they compare
Eswatini currently reports 2,726 constant 2022 US$ against 2,000 constant 2022 US$ in Iraq, a difference of 726 constant 2022 US$.
That makes Eswatini's figure about 1.4 times Iraq's.
Across all 7 years both countries report, Eswatini has been ahead every year.
Eswatini ranks 22nd and Iraq ranks 24th of 56 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Eswatini | Iraq | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20,980 constant 2022 US$ | 4,000 constant 2022 US$ | 16,980 constant 2022 US$ | Eswatini |
| 2020s | 9,624 constant 2022 US$ | 2,400 constant 2022 US$ | 7,224 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Eswatini or Iraq?
- Eswatini, at 2,726 constant 2022 US$ against 2,000 constant 2022 US$ in Iraq as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Eswatini and Iraq?
- 726 constant 2022 US$, with Eswatini ahead.
- How many years of comparable data are there for Eswatini and Iraq?
- 7 years are reported by both, from 2018 to 2024.
- How do Eswatini and Iraq rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Eswatini ranks 22nd and Iraq ranks 24th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.